Cerus Corp. (NASDAQ:CERS) shares traded down 2.8% on Tuesday . The company traded as low as $6.70 and last traded at $6.71, with a volume of 525,765 shares. The stock had previously closed at $6.90.

A number of research analysts recently weighed in on the company. Robert W. Baird set a $10.00 target price on Cerus Corp. and gave the stock a “buy” rating in a report on Saturday, August 6th. FBR & Co restated a “buy” rating on shares of Cerus Corp. in a research note on Monday, July 11th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Cerus Corp. in a research note on Monday, June 20th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Cerus Corp. in a research note on Thursday, July 7th. Finally, Zacks Investment Research downgraded Cerus Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.10.

The company’s market capitalization is $680.96 million. The firm’s 50 day moving average price is $6.77 and its 200-day moving average price is $6.08.

Cerus Corp. (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The company earned $9.25 million during the quarter, compared to the consensus estimate of $8.88 million. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the company earned ($0.17) earnings per share. Analysts anticipate that Cerus Corp. will post ($0.68) earnings per share for the current year.

In related news, CFO Kevin Dennis Green sold 17,150 shares of Cerus Corp. stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total transaction of $116,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

An institutional investor recently raised its position in Cerus Corp. stock. Ameriprise Financial Inc. raised its stake in shares of Cerus Corp. (NASDAQ:CERS) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 245,030 shares of the company’s stock after buying an additional 19,000 shares during the period. Ameriprise Financial Inc. owned 0.25% of Cerus Corp. worth $1,550,000 at the end of the most recent reporting period.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.